You just read:

Astellas and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer

News provided by

Astellas Pharma Inc.

Nov 08, 2017, 08:00 ET